Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current progress in developing mRNA-lipid nanoparticle vaccines against human bacterial pathogens.

Clinical microbiology reviews·2026
Same author

Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice.

NPJ vaccines·2026
Same author

Emergence of distinct Streptococcus pyogenes emm1 and emm12 lineages in China.

Nature microbiology·2026
Same author

The GFI1-FOXO1 axis regulates NK cell maturation and function.

Nature communications·2026
Same author

The role of dopamine decline, astrocyte reactivity, and cerebral small-vessel disease in cognitive aging.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Bacterial reporter-paired scRNA sequencing reveals cross talk between zinc starvation and zinc toxicity in macrophage antibacterial defense.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Jun 4, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.1K

An mRNA vaccine encoding five conserved Group A Streptococcus antigens.

Nichaela Harbison-Price1, Ismail Sebina2, Rhiannon A Bolton2

  • 1Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.

Nature Communications
|July 1, 2025
PubMed
Summary

Messenger RNA (mRNA) lipid-nanoparticle (LNP) vaccines show promise for combating Group A Streptococcus (GAS) infections. This study demonstrates that an mRNA-LNP vaccine effectively protects mice and elicits a robust immune response, highlighting the platform

More Related Videos

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria
08:34

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria

Published on: February 23, 2021

6.9K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 4, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.1K
MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria
08:34

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria

Published on: February 23, 2021

6.9K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.1K

Area of Science:

  • Vaccinology
  • Microbiology
  • Immunology

Background:

  • Group A Streptococcus (GAS) causes significant global disease burden, necessitating new vaccine strategies.
  • Messenger RNA (mRNA) lipid-nanoparticle (LNP) technology offers a novel platform for developing vaccines against bacterial pathogens.

Purpose of the Study:

  • To evaluate the immunogenicity and preclinical efficacy of a multicomponent mRNA-LNP vaccine (Combo#5) against GAS.
  • To assess the immune cell responses and antibody production following vaccination in a mouse model.

Main Methods:

  • Developed a multicomponent mRNA-LNP vaccine formulation (Combo#5) targeting GAS.
  • Administered the vaccine to mice and challenged them with GAS in intraperitoneal and subcutaneous models.
  • Analyzed immune cell populations (CD4+, CD8+ T cells, T follicular helper cells, B cells) and antigen-specific antibody levels.

Main Results:

  • Combo#5 mRNA-LNP vaccination conferred protection against GAS infection in mouse challenge models.
  • Vaccination significantly increased effector CD4+ and CD8+ T cell frequencies and numbers.
  • Enhanced T follicular helper cells, germinal center B cells, memory B cells, and antigen-specific antibody production were observed.

Conclusions:

  • The mRNA-LNP platform demonstrates potential for developing effective vaccines against bacterial pathogens like GAS.
  • The Combo#5 mRNA-LNP vaccine formulation is immunogenic and efficacious in preclinical models.
  • This study supports further development of mRNA-LNP vaccines for infectious diseases.